UBS upgraded Gossamer Bio (GOSS) to Buy from Neutral with a price target of $9, up from $1.25. The firm views the stock’s current risk/reward as “compelling” into the Phase 3 pulmonary arterial hypertension data in February 2026. The probability of success is underappreciated and seralutinib offers a “differentiated” mechanism of action with an inhaled route of administration, the analyst tells investors in a research note. UBS believes the novel mechanism has strong rationale from Gleevec data with improved safety from inhaled delivery.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio’s Seralutinib: Promising Long-Term Therapy with Upcoming Catalysts
- Gossamer Bio Reports Q2 2025 Financial Results
- Gossamer Bio’s Promising Clinical Advancements and Strategic Positioning Earns Buy Rating
- Gossamer Bio reports Q2 EPS (17c) , consensus (18c)
- Gossamer Bio initiated with an Outperform at Scotiabank